References
- AscherBZakineBKestemontPBaspeyrasMBougaraASantiniJA multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar linesJ Am Acad Dermatol200451222323315280841
- CarruthersACarruthersJProspective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytidsDermatol Surg200531101297130316188182
- CarruthersACarruthersJSaidSDose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in femalesDermatol Surg200531441442215871316
- CarruthersJALoweNJMenterMAA multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar linesJ Am Acad Dermatol200246684084912063480
- MonheitGCarruthersABrandtFRandRA randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal doseDermatol Surg2007331 SpecS51S5917241415
- SattlerGCallanderMGrablowitzDNoninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown linesDermatol Surg201036S42146215421134045
- ImhofMKühneUA phase III study of incobotulinumtoxinA in the treatment of glabellar frown linesJ Clin Aesthet Dermatol2011410283422010053
- CarruthersACarruthersJColemanWPIIIMulticentre, randomized, Phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown linesDermatol Surg2013
- HankeWNarinsRSBrandtFA randomized, placebo-controlled, double blind Phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpointDermatol Surg2013
- Bocouture® [package insert] Summary of product characteristicsFrankfurtMerz Pharmaceuticals2010
- BlitzerABinderWJAvivJEKeenMSBrinMFThe management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patientsArch Otolaryngol Head Neck Surg199712343893929109785
- BeerKRBoydCPatelRKBowenBJamesSPBrinMFRapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar linesJ Drugs Dermatol2011101394421197522
- SchlessingerJMonheitGKaneMAMendelsohnNTime to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type ADermatol Surg201137101434144221745254
- FlynnTCCarruthersACarruthersJValidated assessment scales for the upper faceDermatol Surg2012382 Spec30931922316187
- JostWHKohlABrinkmannSComesGEfficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteersJ Neural Transm2005112790591315526142
- RapplTWiednerMKranzlbinderBHaasFIs there a difference in persistence, efficiency and efficacy of 3 BoNT/A-containing products? A double-blind, randomised studyPresented at the 4th International Master Course on Aging SkinHong Kong, China2010 Jul 10–12 Hong Kong, China
- FlynnTCBotulinum toxin: examining duration of effect in facial aesthetic applicationsAm J Clin Dermatol201011318319920369902
- RzanyBFlynnTCSchlöbeAHeinzMHarringtonLLong-term results for incobotulinumtoxinA in the treatment of glabellar frown linesDermatol Surg2013399510323190342
- PragerWWissmüllerEKollhorstBWilliamsSZschockeIComparison of two botulinum toxin type A preparations for treating crow’s feet: a split-face, double-blind, proof-of-concept studyDermatol Surg201036Suppl 42155216021134046
- CarruthersACarruthersJA single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacyJ Am Acad Dermatol200960697297919467368